New HIV Antibody: Best in Class
This issue of IAVI Report marks an important milestone—it ushers the publication into its third decade. It is a testament to the science, which is so dynamic and captivating, that even after 20 years of covering HIV vaccine research there is always more to report on and write about. Some of that scientific work is highlighted here. In this issue, we report on the latest advances from the Conference on Retroviruses and Opportunistic Infections, held this February. We also spoke with Mark Connors of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases about the latest and greatest broadly neutralizing antibody, N6, that his lab isolated and what the advances in antibody discovery mean for HIV prevention.
We also describe in depth the Coalition for Epidemic Preparedness Innovations (CEPI), an organization that sprung up in the aftermath of the latest and largest Ebola outbreak and aims to fill the gaps in vaccine development for emerging pathogens that are considered among the top infectious disease threats. CEPI recently appointed its inaugural chief executive officer, Richard Hatchett, whom we spoke with about his plans for the newly formed coalition.